Galapagos NV: business update: http://t.co/6w1jppWE
posted 4 days ago
FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
Ablynx [Euronext Brussels: ABLX] today announced that it has received a €400,000 milestone payment from its collaboration with Novartis. The payment was triggered by the approval of an Investigational New Drug (IND) application from the U.S. Food and Drug Administration for the Phase I clinical trial for a Nanobody® licensed to Novartis. This is the first development candidate emerging from the licensing agreement between Ablynx and Novartis. read more
PharmaNeuroBoost (PNB) announced today that it obtained approval from the Belgian Authorities and from the Central Ethics Committee to initiate a Proof-of-Concept study in patients with chronic Schizophrenia. The objectives of this study are to evaluate the effect of PNB02, PNB’s second product in development, on functional Magnetic Resonance Imaging (MRI) of the brain and to evaluate the clinical effect of PNB02 treatment in patients with chronic Schizophrenia who are suffering from residual symptoms. read more
Formac Pharmaceuticals NV and its partner W.R Grace and Co., a global leader in silica gel manufacture, today announced the outcome of a phase 1 proof-of-concept study. In this open-label, randomized, single-dose, two-way crossover study, twelve fasted healthy volunteers received treatments consisting of a capsule formulation comprising 33.5 mg of fenofibrate formulated with mesoporous silica (FP 250 formulation) and a marketed capsule based formulation containing 67 mg of micronized fenofibrate (Lipanthyl®). Administration of the FP 250 formulation gave rise to statistically significant higher systemeic exposure (54% increase in dose-normalized AUC0-24h), and higher plasma concentrations (77%increase in dose-normalized Cmax) of fenofibric acid (active metabolite of fenofibrate) when compared to the marketed formulation. No adverse events were reported after administration of the FP 250 formulation. read more
Abbott (NYSE: ABT) and Galapagos (Euronext: GLPG) announced today that they have entered into a global collaboration to develop and commercialize an oral, next-generation JAK1 inhibitor in Phase II development with the potential to treat multiple autoimmune diseases. read more
Galapagos NV (Euronext: GLPG) announced today that GlaxoSmithKline has exercised its option to exclusively license investigational compound GLPG0778 and its corresponding back-up compound GLPG0555, both discovered and developed within GSKs immuno-inflammatory alliance with Galapagos. GSK will have the right to continue the clinical development of these candidate compounds. Galapagos will receive an option fee payment of single-digit million Euros from GSK, which contributes to 2011 Group revenues. Galapagos is eligible, without further financial investment from Galapagos, to receive from GSK more than €34M in future milestones plus royalties on these two compounds. read more
arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody™ platform, announces that it has progressed ARGX-111, its third therapeutic candidate, into formal preclinical development. read more
Ablynx [Euronext Brussels: ABLX] today announced that Boehringer Ingelheim has selected, as part of their strategic alliance, a second Nanobody® candidate for pre-clinical development, which triggered a €5 million milestone payment to Ablynx. read more
TiGenix (NYSE Euronext: TIG) announced today that upon review of the safety data of the first three patients of the second cohort of the company's Phase IIa clinical trial in rheumatoid arthritis (Cx611) it has received the go-ahead from the independent Safety Monitoring Board to recruit and dose the remaining 20 patients of this cohort and to open the third and final cohort. The Phase IIa trial is based on a three-step dose-finding protocol, where each step starts with a safety review of the first three patients after 40 days of dosing. read more
